Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene

Click to increase image sizeClick to decrease image size Disclosure statementThe authors have no conflicts of interest to disclose.Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.